Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Обзорная статья

Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future

Fausto BaldantiDiagnostic and Pediatric Sciences, University of Pavia, Pavia, ItalyNirmal Kumar GangulyIndian Council of Medical Research, New Delhi, IndiaGuiqiang WangThe Center for Liver Diseases, Peking University First Hospital, Beijing, ChinaMartin MöckelCharité – Universitätsmedizin, Berlin, GermanyLuke O'neillTrinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, IrelandHarald RenzDepartment of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, RussiaCarlos Eduardo dos Santos FerreiraAlbert Einstein Hospital, São Paulo, BrazilKazuhiro TatedaDepartment of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, JapanBarbara Van Der PolDepartment of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA
2022en
ABI

Аннотация

A plethora of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic tests are available, each with different performance specifications, detection methods, and targets. This narrative review aims to summarize the diagnostic technologies available and how they are best selected to tackle SARS-CoV-2 infection as the pandemic evolves. Seven key settings have been identified where diagnostic tests are being deployed: symptomatic individuals presenting for diagnostic testing and/or treatment of COVID-19 symptoms; asymptomatic individuals accessing healthcare for planned non-COVID-19-related reasons; patients needing to access emergency care (symptom status unknown); patients being discharged from healthcare following hospitalization for COVID-19; healthy individuals in both single event settings (e.g. airports, restaurants, hotels, concerts, and sporting events) and repeat access settings (e.g. workplaces, schools, and universities); and vaccinated individuals. While molecular diagnostics remain central to SARS-CoV-2 testing strategies, we have offered some discussion on the considerations for when other tools and technologies may be useful, when centralized/point-of-care testing is appropriate, and how the various additional diagnostics can be deployed in differently resourced settings. As the pandemic evolves, molecular testing remains important for definitive diagnosis, but increasingly widespread point-of-care testing is essential to the re-opening of society.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0